These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 25284480)

  • 61. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
    Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
    Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
    PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
    Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
    Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 65. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy.
    Thauvin-Robinet C; Auclair M; Duplomb L; Caron-Debarle M; Avila M; St-Onge J; Le Merrer M; Le Luyer B; Héron D; Mathieu-Dramard M; Bitoun P; Petit JM; Odent S; Amiel J; Picot D; Carmignac V; Thevenon J; Callier P; Laville M; Reznik Y; Fagour C; Nunes ML; Capeau J; Lascols O; Huet F; Faivre L; Vigouroux C; Rivière JB
    Am J Hum Genet; 2013 Jul; 93(1):141-9. PubMed ID: 23810378
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer.
    Li X; Mak VCY; Zhou Y; Wang C; Wong ESY; Sharma R; Lu Y; Cheung ANY; Mills GB; Cheung LWT
    Nat Commun; 2019 Feb; 10(1):716. PubMed ID: 30755611
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
    Kuracha MR; Thomas P; Loggie BW; Govindarajan V
    PLoS One; 2017; 12(6):e0179510. PubMed ID: 28640835
    [TBL] [Abstract][Full Text] [Related]  

  • 68. PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
    Yazdani R; Hamidi Z; Babaha F; Azizi G; Fekrvand S; Abolhassani H; Aghamohammadi A
    Endocr Metab Immune Disord Drug Targets; 2019; 19(7):941-958. PubMed ID: 30799802
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical and immunological assessment of APDS2 with features of the SHORT syndrome related to a novel mutation in
    Szczawińska-Popłonyk A; Bernat-Sitarz K; Schwartzmann E; Piechota M; Badura-Stronka M
    Allergol Immunopathol (Madr); 2022; 50(4):1-9. PubMed ID: 35789397
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
    Steinbrunn T; Stühmer T; Sayehli C; Chatterjee M; Einsele H; Bargou RC
    Br J Haematol; 2012 Nov; 159(4):430-40. PubMed ID: 22985491
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 72. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling.
    Chudasama KK; Winnay J; Johansson S; Claudi T; König R; Haldorsen I; Johansson B; Woo JR; Aarskog D; Sagen JV; Kahn CR; Molven A; Njølstad PR
    Am J Hum Genet; 2013 Jul; 93(1):150-7. PubMed ID: 23810379
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
    Goodwin CB; Yang Z; Yin F; Yu M; Chan RJ
    Haematologica; 2012 Jul; 97(7):1042-7. PubMed ID: 22315502
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pik3r1 Is Required for Glucocorticoid-Induced Perilipin 1 Phosphorylation in Lipid Droplet for Adipocyte Lipolysis.
    Kuo T; Chen TC; Lee RA; Nguyen NHT; Broughton AE; Zhang D; Wang JC
    Diabetes; 2017 Jun; 66(6):1601-1610. PubMed ID: 28292967
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The MAPK pathway as an apoptosis enhancer in melanoma.
    Haydn JM; Hufnagel A; Grimm J; Maurus K; Schartl M; Meierjohann S
    Oncotarget; 2014 Jul; 5(13):5040-53. PubMed ID: 24970815
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Arachidonic acid directly activates members of the mitogen-activated protein kinase superfamily in rabbit proximal tubule cells.
    Alexander LD; Cui XL; Falck JR; Douglas JG
    Kidney Int; 2001 Jun; 59(6):2039-53. PubMed ID: 11380805
    [TBL] [Abstract][Full Text] [Related]  

  • 78. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
    Komatsu N; Fujita Y; Matsuda M; Aoki K
    Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
    [TBL] [Abstract][Full Text] [Related]  

  • 79. cAMP activates TRPC6 channels via the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (PKB)-mitogen-activated protein kinase kinase (MEK)-ERK1/2 signaling pathway.
    Shen B; Kwan HY; Ma X; Wong CO; Du J; Huang Y; Yao X
    J Biol Chem; 2011 Jun; 286(22):19439-45. PubMed ID: 21487005
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway.
    Yu C; Mao X; Li WX
    Biochem Biophys Res Commun; 2005 Jun; 331(2):391-7. PubMed ID: 15850772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.